LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY

Patients with HER2+ breast cancer have frequent LM. A multi center phase 1/2 study assessing safety and efficacy of IT T in LM patients was conducted. The primary endpoint in Phase 2 was response rate (RR). Complete response (CR) required cytologic CR (CCR) + radiographic CR (RCR) + stable clinical...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neurooncol Adv
Autori principali: Kumthekar, Priya, Lassman, Andrew B, Lin, Nancy, Grimm, Sean, Gradishar, William, Pentsova, Elena, Jeyapalan, Suriya, Groves, Morris, Melisko, Melissa, Raizer, Jeffrey
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213435/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz014.025
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi